Initiate additional Phase 1 clinical pharmacology studies of RTA 901
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- Q1 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We plan to initiate additional Phase 1 clinical pharmacology studies in the second quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company's August 2021 filing said the studies had slipped to Q4 2021. Later filings report the additional Phase 1 studies were initiated in Q1 2022, after the Q2 2021 deadline.
-
A Reata Pharmaceuticals Inc. 10-Q filed 2022-05-10
“In the first quarter of 2022, we initiated additional Phase 1 clinical pharmacology studies of RTA 901, including a drug-drug interaction study.” ✓ confirmed on the page
-
A Reata Pharmaceuticals Inc. 10-Q filed 2021-08-09
“Due to slight delays in clinical drug supply, we now plan to initiate additional Phase 1 studies to evaluate the PK and drug-drug interaction potential of RTA 901 in the fourth quarter of 2021” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- Additional Phase 1 clinical pharmacology studies of RTA 901
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Reata Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C358762-024900 · Corrections policy